Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug shows promise in controlling rare stomach cancer

NCT ID NCT00756509

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jan 25, 2026 · Last updated May 15, 2026 · Updated 16 times

Summary

This study tested the drug nilotinib in 34 adults with advanced GIST that could not be removed by surgery. The goal was to see if the drug could shrink or stop the growth of tumors. While not a cure, the treatment helped control the disease in some patients, offering a potential first-line option.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Novartis Investigative Site

    Helsinki, FIN-00029, Finland

  • Novartis Investigative Site

    Lyon, 69373, France

  • Novartis Investigative Site

    Munich, Bavaria, 81377, Germany

  • Novartis Investigative Site

    Bad Saarow, 15526, Germany

  • Novartis Investigative Site

    Essen, 45147, Germany

  • Novartis Investigative Site

    Hanover, 30625, Germany

  • Novartis Investigative Site

    Milan, MI, 20133, Italy

Conditions

Explore the condition pages connected to this study.

GASTROINTESTINAL STROMAL TUMORS